Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-03-14 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain any financial data, results, or detailed presentations. The content is an announcement of meetings rather than a report or transcript. Given the nature of the document as an update on investor meetings, it fits best under Investor Presentation (IP) category, which includes detailed presentations for investors focusing on financials, strategy, and market position. However, since this document only provides a schedule of meetings and not the presentation materials themselves, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other categories more specifically.
2024-03-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI regulations and provides dates and types of meetings but does not contain any financial data, report content, or detailed presentations. The document is short (1661 characters) and serves as an announcement or intimation rather than a report or transcript. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other specific categories like Investor Presentation or Call Transcript, which would contain detailed content.
2024-03-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated March 7, 2024, addressed to stock exchanges regarding the schedule of an analyst/institutional investor meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content is an intimation about the schedule of investor meetings, not a financial report, earnings release, or detailed presentation. The document length is only 1537 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits the category of Investor Presentation (IP) related announcements or scheduling. However, since it only announces the schedule of an investor meeting and does not contain the presentation itself, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement about investor meetings. The document does not contain financial data or detailed presentation materials, so it is not IP or ER. Hence, the most appropriate classification is Regulatory Filings (RNS).
2024-03-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter dated March 4, 2024, addressed to stock exchanges, informing them about the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI regulations for disclosure. The content is a notification of planned meetings rather than a financial report, earnings release, or detailed investor presentation. The document length is short (1866 characters), and it does not contain financial data or analysis. It is an announcement of meetings with investors and analysts, which fits best under the category of Investor Presentation (IP) as it relates to investor relations activities and scheduled meetings with investors, even though it is not a full presentation document itself. However, since it is only a schedule notice and not the presentation material, it is more appropriate to classify it as Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and disclosures that do not fit other categories. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2024-03-04 English
Updates
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of a new President for a wholly-owned step-down subsidiary of Gland Pharma Limited. It includes details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about changes in management or board members. The content focuses on the appointment of a senior executive and provides a brief profile of the appointee. There are no financial statements, earnings data, or report publications. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-02-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled 'Earnings call Transcript- Q3FY24' and contains a detailed transcript of the company's earnings conference call held on February 14, 2024. It includes management commentary on quarterly financial performance, revenue, EBITDA, net profit, R&D expenses, market performance, and Q&A with analysts. The presence of detailed financial data and management discussion confirms this is a full transcript of an earnings call, not just a summary or announcement. Therefore, the document fits the category of a Call Transcript (CT).
2024-02-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.